OrbiMed’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-963,400
| Closed | -$117M | – | 125 |
|
|
2024
Q4 | $117M | Buy |
963,400
+8,900
| +0.9% | +$1.09M | 2.41% | 9 |
|
|
2024
Q3 | $119M | Buy |
954,500
+308,500
| +48% | +$42.6M | 2.17% | 12 |
|
|
2024
Q2 | $102M | Sell |
646,000
-51,500
| -7% | -$6.62M | 2.02% | 12 |
|
|
2024
Q1 | $90.3M | Hold |
697,500
| – | – | 1.65% | 16 |
|
|
2023
Q4 | $67.3M | Buy |
697,500
+168,300
| +32% | +$16.1M | 1.34% | 27 |
|
|
2023
Q3 | $64.1M | Sell |
529,200
-124,800
| -19% | -$14.1M | 1.36% | 25 |
|
|
2023
Q2 | $74.9M | Sell |
654,000
-211,100
| -24% | -$27.2M | 1.36% | 26 |
|
|
2023
Q1 | $119M | Sell |
865,100
-107,200
| -11% | -$13.9M | 2.34% | 11 |
|
|
2022
Q4 | $126M | Buy |
972,300
+53,800
| +6% | +$6.23M | 2.41% | 10 |
|
|
2022
Q3 | $102K | Buy |
918,500
+898,500
| +4,493% | +$90.6M | 1.88% | 17 |
|
|
2022
Q2 | $1.5K | Sell |
20,000
-19,100
| -49% | -$1.41M | 0.03% | 136 |
|
|
2022
Q1 | $3.05M | Sell |
39,100
-19,600
| -33% | -$1.5M | 0.05% | 127 |
|
|
2021
Q4 | $5.29M | Sell |
58,700
-6,000
| -9% | -$513K | 0.07% | 133 |
|
|
2021
Q3 | $5.98M | Hold |
64,700
| – | – | 0.07% | 148 |
|
|
2021
Q2 | $5.03M | Sell |
64,700
-135,578
| -68% | -$10.3M | 0.05% | 149 |
|
|
2021
Q1 | $14.9M | Sell |
200,278
-338,771
| -63% | -$31.3M | 0.14% | 110 |
|
|
2020
Q4 | $91.9M | Hold |
539,049
| – | – | 0.8% | 40 |
|
|
2020
Q3 | $75.7M | Sell |
539,049
-20,600
| -4% | -$3.13M | 0.95% | 32 |
|
|
2020
Q2 | $89.7M | Sell |
559,649
-342,800
| -38% | -$46.6M | 1.26% | 26 |
|
|
2020
Q1 | $88.3M | Buy |
902,449
+136,400
| +18% | +$15.6M | 1.48% | 25 |
|
|
2019
Q4 | $98.9M | Sell |
766,049
-71,300
| -9% | -$7.2M | 1.41% | 25 |
|
|
2019
Q3 | $63.1M | Buy |
837,349
+8,949
| +1% | +$1.06M | 1.2% | 30 |
|
|
2019
Q2 | $126M | Hold |
828,400
| – | – | 1.95% | 13 |
|
|
2019
Q1 | $98.7M | Buy |
828,400
+47,400
| +6% | +$6.09M | 1.53% | 17 |
|
|
2018
Q4 | $85.2M | Sell |
781,000
-73,400
| -9% | -$9.18M | 1.58% | 16 |
|
|
2018
Q3 | $138M | Buy |
854,400
+401,800
| +89% | +$54.9M | 1.66% | 16 |
|
|
2018
Q2 | $59.8M | Buy |
452,600
+131,000
| +41% | +$12.4M | 0.71% | 45 |
|
|
2018
Q1 | $23.8M | Buy |
321,600
+222,200
| +224% | +$14.8M | 0.3% | 75 |
|
|
2017
Q4 | $5.53M | Buy |
+99,400
| New | +$5.27M | 0.07% | 116 |
|
|
2017
Q2 | – | Sell |
-1,054,300
| Closed | -$31.2M | – | 146 |
|
|
2017
Q1 | $31.2M | Buy |
+1,054,300
| New | +$32.6M | 0.35% | 65 |
|
|
2016
Q4 | – | Sell |
-261,800
| Closed | -$16.1M | – | 140 |
|
|
2016
Q3 | $16.1M | Buy |
+261,800
| New | +$7.91M | 0.18% | 82 |
|
Other funds holding SRPT
ACA
FCM
OrbiMed's SRPT Position: Q1 2025 in Review
OrbiMed sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 963,400 shares — an estimated $117M sold.
OrbiMed first reported a position in SRPT in Q3 2016 and held it in 31 quarters. The position peaked at $138M in Q3 2018. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.
- OrbiMed reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
- OrbiMed sold 963,400 Sarepta Therapeutics shares in Q1 2025, an estimated $117M.
- OrbiMed first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 31 quarters.
- OrbiMed's Sarepta Therapeutics position peaked at $138M in Q3 2018.
- 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.
Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.